Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association
You may also be interested in...
Barr is moving ahead with its integration of Pliva, but the firm must overcome several obstacles before it can capitalize on its recently acquired European infrastructure
Generic companies may find it difficult to assess how much supply to produce when a large product loses 180-day exclusivity, comments by Teva Pharmaceuticals USA CEO William Marth suggest
Among a number of potential congressional actions that could benefit the generic industry, generic manufacturers appear to be most bullish about the prospects for the establishment of a pathway for follow-on biologics